QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (UPSTO App No(s). 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428) is Frontier AI/AGI Public Health Trials Sandbox Framework That Provides Free Public Health Services to Registered and Sponsored Visitors/Occupants for RDT&E Under 28 U.S.C. 1498 (Classified as a PPA, OTA Under 10 U.S. Code 4001, 4022), Serving as a Global Intranet of Humans Resident Patients Among Multiple Enclave Communicates ("AI Microcities" or "Smart Health Cities") Living and Learning With AI Robotics for Non-medicinal Treatment.

BRIEF SUMMARY

A. "What is the purpose of this study?"

BACKGROUND. The QAIAx clinical trial (Quantum AI/AGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research initiative examining the viability of AI-governed residential ecosystems for behavioral and mental health intervention. Authorized under 10 U.S.C. 4001 (Defense Sector Research Projects, RDT&E) and supported by pending USPTO applications (Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360), this non-medicinal program investigates whether quantum AI-managed public administration, AI humanoid robotics, holographic holoportation (AI-119 Kikkeri Holo-Suit / "AI Wat Beam Bot"; AI-119 Vulcan QM-Ware or "Quasi-Mind Ware"), and advanced AGI learning machines can reduce housing and care costs while improving mental health outcomes-particularly for persons with addiction and co-occurring psychiatric disorders.

SCOPE & JURISDICTION. The trial operates across a network of self-contained, geodesic dome-enclosed "Microcities" (1,500-15,000 occupants per site) within an affiliate network of 300 communities, spanning North America, South America, Europe, Africa, Oceania, Asia, and the Middle East. Participating host nations are U.S.-allied member states party to the Status of Forces Agreement (SOFA), the Vienna Convention on Diplomatic Relations, and the Hague Convention, alongside related bilateral treaties with the U.S. government.

INTERVENTION & POPULATION: Eligible adults (18+) reside in these Microcities for up to 36 months. Daily life-including housing, utilities, and healthcare-is administered by the ISAC AI/AGI system and robots with minimal human oversight.

CLINICAL TRIAL GOAL(S): The clinical trial program goals are to exemplify a sustainable AGI-managed public administration supported by AI robotics and AGI trans-human and omni-AI machines (e.g., "Q-Men"; "AI-Me"; Beam Bot", "QM-Ware", "AVK Suit") to improve mental health outcomes-especially for those with addiction disorders-and create a financially sustainable model for people on fixed incomes or public assistance.

B. "What conditions does the study focus on?"

The study focuses on adults with:

• Autism spectrum disorders (Asperger's, autism, ADHD, ASD)
• Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA/ecstasy, tobacco/nicotine)
• Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)
• Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).

C. "What does the study involve?"

Eligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital "attitude inoculation" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.

**Who can participate?**

You may be able to join if you:

• Are an adult (18 years or older)
• Have a diagnosis of one of the listed mental-health or addiction disorders
• Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organization (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole/probation officer, judge)
• Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.

Participants who are veterans, receive public assistance (e.g., VA disability, SSDI/SSI, Medicaid, Medicare), or are experiencing homelessness may be prioritized.

**Where is the study taking place?** The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.

**Who is sponsoring the study?** The study is sponsored by Veterans Recovery Network Inc., a SCDV-owned non-profit organization, in collaboration with AI-119 Vulcan Project Research & Educational Technology Co. (PRETCO). The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §§§§ 4001, 4021, 4022, and 4023) and is part of a Cooperative Research and Development Agreement (CRADA) with participating segments or RDT&E programming missions of the United States Defense Department (DoW).

This summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.